We show that expression in fibroblasts of a single cDNA, encoding the erythroid DNA-binding protein Eryfl (GF-1, NF-El), very efficiently activates transcription of a chicken a-globin promoter. trans-Activation in these cells occurred when Eryfl bound to a single site within a minimal globin promoter. In contrast, efficient activation in erythroid cells required multiple Eryfl binding sites. Our results indicate that mechanisms exist that are capable of modulating the trans-acting capabilities of Eryfl in a cell-specific manner, without affecting DNA binding. The response of the minimal globin promoter to Eryfl in fibroblasts was at least as great as for optimal constructions in erythroid cells. Therefore, the assay provides a very simple and sensitive system with which to study gene activation by a tissue-specific factor.
The regulation of globin genes involves restriction of expression to cells of the erythroid lineage; other (perhaps distinct) mechanisms determine which members of the gene family are expressed during a particular stage of development. A number of DNA-binding proteins have been identified which interact with sequences that are important for transcription of the various chicken globin genes (reviewed in reference 7); at least some of these factors are present in many cell types and therefore may also regulate the expression of nonerythroid genes. Other binding activities are abundant only at particular stages of erythroid development and therefore might be involved in regulating stage-specific expression of particular globin genes (5, 10, 13) .
We identified an erythroid DNA-binding protein named Eryfl (mammalian homologs are also referred to as GF-1 [21] and NF-E1 [31] ) that binds to regulatory regions of every chicken globin gene (8) and have cloned the Eryfl cDNA (6) . Because the factor is expressed in all erythroid lineages, we proposed that Eryfl may be a key regulatory molecule in the early events determining erythroid-specific expression (8) . As further evidence, Eryfl interacts with regulatory elements of erythroid-specific genes in addition to globin genes (2, 24, 29) .
We have previously shown that the Eryfl cDNA encodes the sequence-specific DNA-binding activity identified in extracts of chicken erythroid cells (6) and that mutation of Eryfl binding sites results in a decrease in expression from a linked promoter in the same cells (8, 27 ). However, it is possible that for activation of globin gene expression, additional cell-specific factors are required. To address this question, we have asked whether a globin promoter can be activated in a nonerythroid environment by Eryfl.
MATERIALS AND METHODS
Cell culture and DNA transfection. Chicken fibroblast cells (CEFs) were prepared by trypsin digestion of 11-day embryos. Following expansion of the adherent cell population, cells were divided into aliquots and frozen in 10% dimethyl sulfoxide. Cells were then thawed for use in transfection experiments; an aliquot could be passaged up to 10 times without significant changes in growth rates, at which time a fresh aliquot was expanded. Cells were maintained in Dulbecco modified Eagle medium containing 8% fetal bovine serum, 2% chick serum, and antibiotics, including amphotericin B (Fungizone) (all from GIBCO). Similar results were obtained from different passages and aliquots of CEF cells or from cells prepared instead from breast muscle tissue. Chicken erythroid cells were prepared by bleeding 10-day embryos.
Transfection into embryonic erythroid cells was performed as described previously (12, 25) . For each assay, a cell concentration corresponding to an A412 value of 20 (about 1.7 x 108 cells; 18) was osmotically shocked in 0.25 M NH4Cl for 35 min at 25°C. For transfection, swelled cells were incubated in a 0.5-ml solution of L-15 medium (Flow Laboratories) containing DNA (2 ,ug/ml) and DEAE-dextran (200 ,ug/ml); (Pharmacia) for 10 min at 37°C. After washing, cells were incubated for 40 to 48 h in L-15 medium containing 5% fetal bovine serum, 2% chick serum, and antibiotics. Cells were transfected and incubated in sterile 1.5-ml microcentrifuge tubes (Sardstedt). Transfection of nonerythroid cells was performed by using a cationic lipid (DOTMA or lipofectin; 9) according to the instructions of the manufacturer (Bethesda Research Laboratories). In a standard assay, 0.75 ml of medium (without serum) containing DNA (3 ,ug (28) . For each transfection, a 25-,ul sample was analyzed for ,B-gal activity at 37°C for 20 min. A volume (usually about 5% of the sample) containing a defined amount of p-gal activity was then used to assay for CAT activity. Erythroid cells were spun down, washed in PBS, and similarly lysed. One half of each sample was then assayed for chloramphenicol acetyltransferase (CAT) activity.
All CAT assays were performed for 30 min at 37°C and analyzed by thin-layer chromatography as described previously (28) . Following autoradiography, the regions of the thin-layer chromatography plate containing labeled chloramphenicol or its acetylated forms were individually cut out and counted by liquid scintillation to determine the conversion percentage. In the case of transfections including paD3 and pRSV20-2, this was typically about 40%. Assays in which the conversion was greater than 60% were repeated with less lysate. After subtraction of the percent conversion using lysate from a mock transfection (less than 0.1%), all results from a single set of transfections were expressed relative to the basal activity obtained from pxD3 in the same set. The results from multiple independent experiments were then combined to determine the mean activities and standard sample deviations shown in the figures.
RNA for primer extension experiments was prepared from transfections performed under standard conditions except scaled up threefold, using 100-mm culture dishes. Cells were harvested, and a sample from each was used to measure P-gal activity. The remaining cells were lysed in 4.0 ml of RNAzol (Cinna Biotecx); RNA was prepared as instructed by the manufacturer. DNA was removed by treatment with RNase-free DNase I (Boehringer Mannheim). For each sample, 0.2 pmol of 5'-end-labeled primer complementary to proper expression from the long terminal repeat, while in pRSV20-1 the cDNA is inverted so that the noncoding strand is transcribed.
The reporter plasmids pxD1 and paD/J were provided by J. Knezetic and have been described elsewhere (referred to as D': and D':J, respectively; 17). To construct the other reporter plasmids, the sequences from a PstI site at -10 in the aD-globin promoter to a PstI site downstream of the CAT gene were isolated from paDi and inserted into the PstI site in the polylinker of pBSIISK-(Stratagene). The resulting plasmid is designated paD2. The natural (paD3) or mutated (paD4, paD9, paDl0, paDll, and paD12) promoter sequences were then synthesized from the -10 PstI site to -65 (where an SpeI site was created) and inserted in the proper orientation of PstI-SpeI-digested paD2. Synthetic (20- CAT message was hybridized to 50 ,ug of total RNA in 20 ,ul of a solution consisting of 0.2 M NaCl and 0.01 M piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES; pH 6.4). The solution was heated at 75°C for 10 min and allowed to cool slowly to 37°C to facilitate annealing. The primer was extended by avian reverse transcriptase (Bethesda Research Laboratories). RNA was then hydrolyzed by incubation of the purified sample in 0.1 N NaOH for 10 min at 37°C prior to analysis of the extension products by gel electrophoresis.
Initiation that occurs at the proper start site of the aD_globin promoter results in an extended product of 161 nucleotides.
Plasmid constructions and oligomer probes. The cDNA expression vectors were derived by using DNA fragments from pRSVCAT (11) . The vectors were constructed by inserting a HindIII fragment containing the enhancer and promoter of the Rous sarcoma virus long terminal repeat upstream of the full-length Eryfl cDNA (clone 20; 6) in the vector pBSIISK-(Stratagene). Downstream of the cDNA sequences, the simian virus 40 splicing and polyadenylation signals from pRSVCAT were inserted. Vector pRSV20-2 contains the cDNA sequences in the correct orientation for DNA-protein binding assays. Nuclear extracts were prepared from 10-day embryonic erythroid cells as described previously (8) . To prepare extracts from CEF cells, the cells were first transfected under standard conditions except scaled up threefold, using 100-mm culture dishes. After 40 to 48 h, cells were harvested into TEN buffer by scraping and washed in PBS. Nuclear extracts were prepared exactly as described previously (4); all buffers included 87.5 ,ug of phenylmethylsulfonyl fluoride, 0.5 ,ug of leupeptin, 0.7 ,ug of pepstatin, and 50 ,Ig of antipain per ml. The nonerythroid extracts were made by using fivefold fewer cells (per volume of extract) relative to those made from erythroid cells (erythroid cell extracts were more concentrated).
The gel mobility shift assays were performed as described previously (6) ; gels were 8% polyacrylamide and were run in 10 mM Tris base-10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES)-1 mM EDTA. When used, unlabeled specific competitors were added to the reaction mix prior to addition of protein. DNase I footprinting experiments were performed as described previously (13) previous results had shown a more extensive a D_globin promoter region, containing 289 bp upstream of the mRNA cap site (paD1), to be only weakly active in embryonic erythroid cells (17) . In that study, the 289-bp promoter was stimulated by an enhancer sequence from the a-globin locus containing three Eryfl binding sites (paD/J). Therefore, we analyzed the effect of additional Eryfl binding sites on the activity of the aD-globin promoter in either primary erythroid cells or the nonerythroid CEF cells.
The reporter constructs were first transfected into primary embryonic erythroid cells (12, 18) to determine whether expression from the CAT gene is dependent on the presence of binding sites for the endogenous Eryfl (Fig. 2) . Deletion of the aD_globin promoter containing 289 bp upstream of the mRNA cap site (paDj) to position -65 (paD3) resulted in a sevenfold drop in CAT activity, indicating that positive regulatory elements are present in the upstream promoter region (-289 to -65). Mutation of paD3 at the Eryfl binding site (as in paD4) reduced expression a further fivefold, essentially to a background level. Therefore, the paD3 reporter contains a minimal promoter that in erythroid cells is dependent on a single Eryfl binding site.
Consistent with previous results (17), we found that addition of the ax-globin enhancer downstream of the CAT gene stimulated expression from paD1 about 10-fold in erythroid cells. Addition of synthetic Eryfl binding sites (derived from one of the sites present in the ,B-globin enhancer) upstream of paD3 also increased expression; a reporter containing three (paD5) or five (paD6) additional upstream Eryfl binding sites expressed CAT at levels 23-or 110-fold, respectively, over paD3. In the latter case, this is even higher than activity from the paD/J construct containing the enhancer, demonstrating that the synthetic sites function as positive elements in the erythroid cells. The effect on expression was entirely dependent on binding by Eryfl, as mutation of the binding sites abolished the effect (paD4, paD7, and paD8).
Efficient trans-activation in CEF cells requires only a single Eryfl binding site. We next assayed the activity of these reporters in CEF cells (Fig. 3) , either in control experiments (cotransfecting pRSV20-1) or in the presence of the expressed Eryfl cDNA (cotransfecting pRSV20-2). Expression of the Eryfl cDNA resulted in a trans-activation from the paD3 minimal promoter of 360-fold (mean from 10 independent experiments). However, additional Eryfl binding sites did not necessarily facilitate higher levels of trans-activation. The construction with three synthetic sites (paD5) was trans-activated 500-fold over the basal level (note that the CAT activity was actually somewhat lower but that the basal level of the reporter was also lower than in the case of paD3). The construction with five additional sites (paD6), which was 100-fold more active than the minimal promoter in erythroid trans-activation of the paD1 construct yielded CAT activity threefold above that obtained by trans-activation of the minimal (-65) paD3 promoter (Fig. 3) . However, because basal expression of the paD1 reporter in CEF cells (in control experiments cotransfecting pRSV20-1) was 10-fold greater than that of paD3, the activation of paD1 relative to its basal expression was actually somewhat less than observed with paD3. This result indicates that the contribution of positive elements upstream of the minimal promoter, detected also by transfection into erythroid cells (Fig. 2) (Fig. 4 and data not shown) . CAT activity obtained from CEF cells was the same regardless of whether 0.25, 0.5, 1.0, or 2.0 ,ug of pRSV20-2 was included in the transfection (Fig. 4a) (Fig. 4b) (14) . In addition, the TATA box at -30 presumably binds the general RNA polymerase factor TFIID (reference 3 and references therein). We introduced mutations into each of these putative elements within the paD3 promoter region (Fig. 5a ) and assayed for the effect of these mutations on expression in erythroid cells and trans-activation by Eryfl in CEF cells.
The results of the promoter mutations are shown in Fig.   5c ; in all cases, the mutations had deleterious effects on the activity of the promoter in erythroid cells, although the significance is unclear, as the normal activity of the minimal promoter is quite low in these cells. GAT core consensus binding sequences, both of which are mutated in the non-trans-activated minimal promoter construct paD4. Although only the downstream GAT element was protected from DNase I digestion in nuclei, the upstream GAT was also protected by concentrated protein extracts in vitro (16) . We found that mutation of the upstream GAT motif (paD12) decreased trans-activation about fourfold, similar to mutation of the G+C element, demonstrating that primary activation by Eryfl occurs through the downstream GAT motif. As shown below, the aD promoter bound only one molecule of Eryfl, at the downstream motif; mutation of the upstream GAT motif in paD12 resulted in a weaker binding site. Finally, we considered whether the Eryfl binding site in the minimal promoter is functionally distinct from the synthetic binding sites that we have appended. The synthetic sites were derived from a strong binding site present in the chicken,-globin enhancer and functioned in erythroid cells (Fig. 2) . Nevertheless, it was in principle possible that they function in erythroid cells in conjunction with a factor missing from CEF cells, while only the native aD promoter site (which has distinct adjacent sequences) can function in CEF cells. This activity would presumably be mediated by a cooperative interaction between expressed Eryfl and a factor present in CEF cells but absent from erythroid cells. To test this, we inserted the synthetic sites upstream of the mutated (paD4) promoter (Fig. 5b) and assayed activity in erythroid or CEF cells. In either cell type, the synthetic sites (in either orientation) functioned for activation of the minimal promoter (Fig. Sc) . In all cases, the mutation of the native site caused a significant decrease in the activity of the promoter that was not entirely compensated for by the upstream synthetic sites. The data indicate either that the function of Eryfl under these condition is dependent on its relative distance from the cap site (consistent with the high level of activity observed with the paDll construct) or Additional, faster-mobility complexes were also formed with the Eryfl probe; these resulted from binding of proteolytic products of the expressed cDNA that retained DNAbinding activity and appeared to accumulate as a consequence of overexpression in the nonerythroid cells (data not shown). Because this is the only obvious difference that we find between endogenous Eryfl and the protein expressed in CEF cells, it is important to determine that the full-length and not the proteolytic products are responsible for the efficient trans-activation of the aD_globin reporters in CEF cells. It is conceivable that proteolysis of Eryfl in fibroblasts removes a repressor domain to release the protein from normal suppressed regulation. For example, removal of such a domain in the N-terminal region of c-jun results in significantly greater transcriptional activity (1). Preliminary mu- To determine whether the Eryfl binding site in paD3, containing two adjacent GATA consensus core motifs, binds one or two molecules of Eryfl (or other proteins), we used mutated oligonucleotide duplexes as probes in the gel mobility shift assay (Fig. 6c) . As controls, we used DNA probes that are known to contain either a single binding site (probe 1) or two adjacent sites from the ,-globin enhancer that bind independently (8) two molecules of Eryfl (probe 2).
When probe 3 (containing the nonmutated sequence) was used, a single complex was formed that was identical to the complex formed by using control probe 1, containing only a single binding site. Even under conditions of increased protein, in which both sites of probe 2 were bound to form a dimer complex (large arrow, Fig. 6c ), probe 3 did not form a dimer complex. Mutation of the upstream GAT motif (probe 4) resulted in about a twofold reduction in affinity relative to the wild-type sequence, whereas mutation of the downstream GAT (probe 5) or mutation of both sites (probe 6) resulted in a complete loss of complex formation. Identical results were obtained by using extracts from CEF cells transfected with pRSV20-2 (not shown). We conclude that the aD-globin minimal promoter binds a single molecule of Eryfl that recognizes primarily the downstream GAT motif, but that in the presence of both GAT motifs, Eryfl binds with a twofold-higher affinity, facilitating a fourfold-higher level of trans-activation (compare paD3 with paD12 in Fig.   5 ). Mutation of a complex Eryfl binding site that affects transcription but does not strictly correlate with a change in binding affinity has been noted in other systems (21) .
DISCUSSION
We have shown that the Eryfl cDNA, previously found to encode a tissue-specific DNA-binding activity (6) , also encodes the transcriptional activation function implied by mutation studies of DNA regulatory elements (8, 21, 27) .
In drawing conclusions from these experiments, it must be kept in mind that we detect CAT activity from the reporter as an indirect measure of transcriptional enhancement. We note that reporters containing mutated Eryfl binding sites (e.g., paD4) show a small (about fivefold) but consistent level of trans-activation. This could be due to any of several causes: binding of the expressed Eryfl at fortuitous sites present in the reporter vector, true trans-activation in the absence of DNA-binding, or activation of transcription elsewhere on the reporter plasmid that reads through the CAT gene. We are further investigating this phenomenon.
Nevertheless, in CEF cells that do not contain endogenous Eryfl, with a reporter containing only a single Eryfl binding site, we find that Eryfl expression stimulates CAT activity 2 orders of magnitude over the basal level of the promoter. This trans-activaton is dependent both on expression of the cDNA in the correct orientation and on a functional DNA-binding site. In the case of the paD3 reporter, we have shown that Eryfl directs accurate initiation of RNA transcripts.
The mechanism by which Eryfl stimulates transcription appears to be different or modified in erythroid compared with nonerythroid cells. A single high-affinity binding site suffices to direct efficient trans-activation in the nonerythroid cells, while high levels of activation in erythroid cells requires either multiple Eryfl binding sites or the addition of At this point, we are unable to distinguish between two models, either of which could explain these observations (Fig. 7) . One possibility is that Eryfl activity is suppressed in erythroid cells, directly or indirectly, to make it a less active transcription factor, without altering its DNA-binding function. In this case, full activity could be obtained only when multiple molecules are bound in a regulatory region. According to this view, the role of an enhancer would be to serve as a site for interactions that overcome the repression placed upon Eryfl by the erythroid environment. Such a regulatory mechanism might be important to prevent a powerful transcriptional activator from wreaking havoc in the cell in which it is expressed. The repression mechanism need not be present in nonerythroid cells (such as CEF cells), because Eryfl is normally never expressed in these cells.
An alternative possibility is that Eryfl is modified or complemented to make it a superactivator in CEF cells. Binding of additional Eryfl molecules at the upstream synthetic sites may have little effect if the minimal promoter is already operating at the maximal rate. Similar cell-specific activities of a transiently expressed transcription factor have recently been noted in other systems (30 
